FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Breast Cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Some women with early-stage breast cancer forego chemotherapy
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with node-negative, ER-positive breast cancer
A research study named the “Trial Assigning Individualized Options for Treatment” (TAILORx) asked whether chemotherapy is beneficial for women who have mid-range Oncotype DX tumor recurrence scores. This trial — the largest breast cancer treatment trial ever conducted— showed that endocrine therapy alone was as effective as endocrine therapy plus chemotherapy in women with certain types of early-stage breast cancer. The results of this trial are expected to be immediately practice changing (7/20/18)
Read MoreArticle : High health insurance deductibles can interfere with breast cancer treatment decisions
Most relevant for: People diagnosed with breast cancer
A New York Times article published on May 4, 2018 examines the impact of high insurance deductibles on breast cancer treatment. (7/12/18)
Read MoreRelevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsStudy : Evaluation of some direct-to-consumer genetic testing reveals inaccuracies and misinterpretations
Relevance: Medium
Strength of Science: Medium
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: People who are considering or have had direct-to-consumer testing
A clinical genetic testing laboratory examined results from direct-to-consumer genetic testing ordered directly by patients. They found many instances of false positives—reported mutations that were not actually present—and in some cases, reports of variants that "increased risk," but were actually benign. This study emphasized the importance of involving genetics experts in the interpretation of genetic test results. (6/28/18)
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Disparities in research impact breast screening guidelines
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Women at average risk for breast cancer
For women at average risk of breast cancer, the United States Preventive Services Task Force (USPSTF) currently recommends beginning annual breast cancer screening at age 50. However, because these guidelines are largely based on data from white women, they may not be sensitive to racial differences. A new study assesses the age distribution of breast cancer cases across race/ethnicity in the U.S. (6/21/18)
Read MoreRelevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsStudy : Mutations in Lynch syndrome genes MSH6 and PMS2 may be associated with breast cancer
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
View Related Clinical TrialsMost relevant for: Women with an MSH6 or PMS2 mutation
Some women with mutations in MSH6 and PMS2, two Lynch syndrome genes, may have a modest (2 to 3-fold) increased risk for breast cancer. (6/14/18 updated 09/25/19)
Read MorePersonal Story : Juliet's story: No reconstruction is a post-mastectomy option
Most relevant for: Women who have had or are considering mastectomy without reconstruction
In a March 2018 article from breastcancercare.org, Juliet conveys her personal experience with a breast cancer diagnosis and her decision to not have her breasts reconstructed after her mastectomy. She details the emotional complexity of her thought process and the empowerment she felt in her decisions. (5/24/18)
Read MoreRelevance: Medium
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Metastasis is affected by wound healing and inflammation in study on mice
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: Cancer patients who will be, or have recently undergone surgery
This study in mice looked at how wound healing after surgery affects metastasis. Researchers found that wound healing caused changes in the mouse immune system that allowed some cancer cells to grow, but that treatment with a non-steroidal anti-inflammatory drug (NSAID) reduced inflammation and frequency of metastases. While this research is promising, it remains to be seen if similar effects occur in humans. (5/17/18)
Read MoreRelevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Childbearing after breast cancer among young survivors
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: Young breast cancer survivors who wish to become pregnant
Women who are diagnosed with breast cancer as an adolescent or young adult often have not yet begun or finished childbearing. Researchers studied the impact of breast cancer and related treatment on birth rates and birth outcomes in young survivors. Overall, adverse birth outcomes were not increased for young survivors compared to women without cancer. However, women with ER-negative breast cancers had a modestly higher frequency of preterm and low weight births. The authors highlight the need for fertility counseling and potential fertility preserving methods prior to treatment. (5/10/18)
Read MoreGuideline : American Heart Association examines the challenges of cardiovascular disease and breast cancer
Most relevant for: People diagnosed with breast cancer
Current breast cancer treatments can negatively affect cardiovascular health. Recently, the American Heart Association released its first scientific statement on cardiovascular disease and breast cancer. This statement includes a comprehensive overview of the prevalence of both diseases, shared risk factors, cardiotoxic effects of therapy and the prevention and treatment of cardiovascular disease in breast cancer patients. (5/2/18)
Read MoreArticle : The right not to know when not knowing is dangerous
Most relevant for: People with Icelandic heritage
Healthcare providers are bound by the guiding principle of doing no harm. But how does this concept apply to their patients who have not consented to genetic testing or who do not want to know their results? In that case, is providing test results more harmful or not? Anna Clausen explores these issues in the context of breast cancer gene testing in her Global Health Now article “The Right Not to Know: When Ignorance is Bliss but Deadly.” (4/20/18)
Read MoreSearch XRAY studies and Articles
This Portal Sponsored By: